Drugs / ConS UFO
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03816137 Comparator | Mar 2019 → Dec 2022 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ConS UFO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03816137 ↗ |
| Known as | ConS UFO gp140 | “Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140.” NCT03816137 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140.” NCT03816137 ↗ |